Ann: Ryoncil Pricing Set and Available This Quarter, page-221

First 221 Last

Share
Profile

Follow
Pledge

8,874 Posts.

1465

27/02/25

15:46

Post #: 78058507
Share

Originally posted by Bazsa: ↑

Great post,

"When are those wonderful Australian biotech and healthcare analysts going to do their job and make their clients money."

Could I suggest that they are doing it now and they have been doing it for some time.

Many times these guys remain silent or perhaps even put out news or tall stories to create a very positive buying environment.

Look what happened when Dr George was buying. Did we hear any thing about the probability of ASX 200 inclusion. No, silence was the go. We know from the turn over it was not just the Dr. buying. Our not so much good friend over on the other sight hit me for six , even came up with his calculations that showed we had next to no chance. How funny, a couple of weeks later in came the reports of "very strong probability of inclusion in the March rebalance " this at a time when GG had stopped buying and the probability of inclusion fell away big time. Interestingly ET's annalise was at no stage any were near hitting the inclusion criteria. ET's backflip was breathtaking.

ET's knowledge is undeniable, he shares a lot of very useful information nevertheless he is obviously connected to instos, he is there tool to spread misleading information and negativity to our very capable board. His defence of M & G is in my opinion totally invalid. They were in significant part responsible for what was very nearly a failed CR at 30 cents and the potential bankruptcy of our company. For those that think I am jumping at shadows I would suggest taking a look at the last M&G notice .

It is with very good reason that our last two CRs have been designed in such a way to prevent the likes of M&G buying in.
These guys are multiples worse than any shorter.

Expand

What a load of utter BS.

Poor Silviu. Awwwww, there's nothing he could do, M&G MADE him run the business into the ground and they made him and GG buy all those shares at 30c..............??!!

You are utterly broken.

You're the John Travolta of the ScienceTology group.

MSB Price at posting: $2.50 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

IXR

Ionic Rare Earths falls -7% as momentum slips on vague production update

HAR

Haranga jumps +7% on Lincoln acquisition

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

NUZ

Neurizon inks $1.5M loan against R&D Tax Rebate

Oz core inflation at 2.7%; August cut odds still unclear; ASX200 rises

First 221 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.44		Change -0.055(2.21%)		Mkt cap ! $3.110B

Open	High	Low	Value	Volume
$2.47	$2.47	$2.34	$8.592M	3.559M

Buyers (Bids)

No.	Vol.	Price($)
56	35889	$2.43

Sellers (Offers)

Price($)	Vol.	No.
$2.44	15551	29

View Market Depth

No.	Vol.	Price($)
45	31245	2.430
12	45176	2.420
11	73655	2.410
12	66386	2.400
8	53205	2.390

Price($)	Vol.	No.
2.440	7810	11
2.450	49039	31
2.460	62043	15
2.470	103118	11
2.480	95534	10

Last trade - 15.13pm 30/07/2025 (20 minute delay)

MSB (ASX) Chart

Ann: Ryoncil Pricing Set and Available This Quarter, page-221

Ionic Rare Earths falls -7% as momentum slips on vague production update

Haranga jumps +7% on Lincoln acquisition

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

Neurizon inks $1.5M loan against R&D Tax Rebate

Oz core inflation at 2.7%; August cut odds still unclear; ASX200 rises

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Ryoncil Pricing Set and Available This Quarter, page-221

Top Stories

Ionic Rare Earths falls -7% as momentum slips on vague production update

Haranga jumps +7% on Lincoln acquisition

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

Neurizon inks $1.5M loan against R&D Tax Rebate

Oz core inflation at 2.7%; August cut odds still unclear; ASX200 rises

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News